HomeUKMedherant Raises £3M in Funding

Medherant Raises £3M in Funding

-

Medherant

Medherant, a Coventry, UK-based biotechnology company advancing a testosterone patch for women with menopausal symptoms, raised £3M in funding.

Mercia Asset Management made the investment.

The company intends to use the funds to accelerate its growth and research efforts.

Led by CEO John Burt, Medherant is a clinical-stage company developing a testosterone replacement patch for women with menopausal symptoms, which is based on a proprietary adhesive developed by its scientists. The patch delivers the correct amount and would have to be changed twice a week. The University of Warwick spin-out aims to begin clinical trials later this year and to gain regulatory approval in the UK and internationally.

FinSMEs

04/04/2023

THE DAILY NEWSLETTER - SIGNUP